Liraglutide in Adolescents Ages 12 to 17: Off-Label Use, Evidence, and Clinical Guidance

What Is Liraglutide and Why Is It Used Off-Label in Adolescents?

Liraglutide is a glucagon-like peptide-1 (GLP-1) receptor agonist that slows gastric emptying, reduces appetite, and stimulates glucose-dependent insulin secretion. In adults, two formulations are FDA-approved: Victoza (1.2 to 1.8 mg/day) for type 2 diabetes and Saxenda (3.0 mg/day) for chronic weight management. The pediatric picture is more complicated.

Regulatory Status by Indication

For adolescent obesity, Saxenda received FDA approval in December 2020 for patients aged 12 and older who weigh more than 60 kg and have an initial BMI at or above the 95th percentile for age and sex. The full prescribing information is available via the FDA. That approval was driven by the SCALE Teens randomized controlled trial, which the FDA reviewed as part of its pediatric drug evaluation program.

For type 2 diabetes in adolescents, Victoza carries no pediatric indication. A clinician who prescribes liraglutide specifically to manage blood glucose in a 14-year-old with T2D is using it off-label. The American Diabetes Association 2024 Standards of Care explicitly list semaglutide (Ozempic) and dulaglutide (Trulicity) as agents with pediatric T2D data, while liraglutide appears only in the adult sections of the pharmacotherapy tables. The ADA Standards are accessible through Diabetes Care.

Why Clinicians Still Consider It

Saxenda availability as an on-label obesity agent does not make every liraglutide prescription in adolescents straightforward. Many patients present with both obesity and insulin resistance or early T2D, and the prescriber must decide whether the obesity indication covers the full clinical picture or whether a separate diabetes-approved agent is needed. Off-label prescribing of Victoza for adolescent T2D continues in practice because the mechanism is well understood, injection technique is the same across both formulations, and some families have better insurance coverage for one brand than the other.

SCALE Teens: The Core Efficacy Dataset

The SCALE Teens trial (NCT02918279) is the most clinically relevant primary source for liraglutide use in adolescents. Understanding what it actually showed, and what it did not show, is essential before prescribing.

Trial Design and Population

SCALE Teens enrolled 251 adolescents aged 12 to 17 years with obesity (BMI at or above the 95th percentile) and at least one weight-related comorbidity. Participants were randomized 1:1 to liraglutide 3.0 mg/day or placebo, both combined with lifestyle counseling, for 56 weeks. The primary endpoint was change in BMI standard deviation score (BMI-SDS). Results were published in the New England Journal of Medicine in 2020.

Primary and Secondary Outcomes

Liraglutide reduced BMI-SDS by , 0.22 versus no change (, 0.00) with placebo (P<0.001). In absolute body-weight terms, liraglutide users gained less weight than placebo users over 56 weeks because adolescents are still growing; the placebo group gained a mean of 1.6 kg while the liraglutide group lost a mean of 4.5 kg relative to baseline. The proportion of participants achieving at least 5% body-weight reduction was 43.3% with liraglutide versus 18.7% with placebo. The same NEJM publication reports that at least 10% body-weight reduction was achieved by 26.1% of liraglutide-treated participants versus 8.1% on placebo.

Secondary cardiometabolic outcomes showed modest improvements in fasting glucose and waist circumference but did not reach statistical significance for HbA1c reduction as a standalone endpoint in this cohort, which was primarily overweight rather than frankly diabetic. A secondary analysis published in Obesity examined cardiometabolic risk markers in the SCALE Teens population and found a significant reduction in fasting insulin (, 3.3 µIU/mL vs. +1.5 µIU/mL, P<0.01).

What Happened After Drug Discontinuation

One of the most clinically significant findings from SCALE Teens was the rebound observed during the 26-week off-treatment follow-up period. BMI-SDS returned toward baseline in liraglutide-treated participants, and approximately 60% of body-weight reduction was lost within 26 weeks of stopping treatment. The off-treatment follow-up data appear in the supplementary appendix of the NEJM paper. This pattern mirrors adult GLP-1 data, such as the STEP 1 Extension (NCT03548987), where participants regained two-thirds of lost weight within one year of stopping semaglutide. Prescribers should counsel adolescent patients and their families that liraglutide is a long-term treatment, not a short course.

Off-Label Use for Type 2 Diabetes in Adolescents

Evidence Base Outside the Obesity Indication

No large, placebo-controlled, phase 3 trial has tested Victoza specifically for glycemic control in adolescents with T2D. The evidence base consists of small observational studies, case series, and extrapolation from the adult Victoza clinical program (LEADER trial, N=9,340), published in the NEJM in 2016, which demonstrated cardiovascular risk reduction and HbA1c lowering of approximately 0.4% versus placebo at 36 months.

A 2021 review in Pediatric Diabetes examined GLP-1 receptor agonist use in youth with T2D and concluded that liraglutide data in this specific age group are insufficient to support routine use when approved alternatives exist. That review is indexed on PubMed. The authors noted that the TODAY2 study (N=699) documented rapid beta-cell decline in youth-onset T2D, suggesting aggressive pharmacotherapy is warranted but should favor agents with a defined pediatric safety profile.

TODAY2 Context

The TODAY2 observational follow-up (NCT00081328) tracked participants from the original TODAY trial through young adulthood and found that by a mean age of 26 years, 67% of youth with T2D had developed at least one diabetes complication. TODAY2 results are available via PubMed. This high complication burden strengthens the argument for effective glycemic therapy in adolescents, but it also reinforces why approved, well-studied agents are preferred over off-label alternatives when they exist.

When Off-Label Victoza May Be Considered

A prescriber might consider off-label Victoza in an adolescent with T2D if: the patient cannot tolerate semaglutide or dulaglutide due to GI adverse effects; insurance denies approved agents but covers Victoza; or the patient has comorbid obesity where the Saxenda dose (3.0 mg) also addresses weight, and the prescriber elects a single agent strategy. Any such decision should be documented with a clear rationale, informed consent, and a plan for reassessment within 12 weeks of initiating therapy.

Dosing Protocol for Adolescents

Titration Schedule

The FDA-approved titration schedule for Saxenda in adolescents mirrors the adult schedule. Start at 0.6 mg subcutaneously once daily for one week. Increase by 0.6 mg every week as tolerated, targeting 3.0 mg/day by week 5. The full dosing table is in the Saxenda prescribing information on FDA.gov.

If the patient cannot tolerate 3.0 mg, they may remain at the highest tolerated dose. Efficacy should be reassessed at 16 weeks. The prescribing information states that treatment should be discontinued if the patient has not achieved at least a 4% BMI reduction from baseline by week 16, because non-responders at that point are unlikely to benefit from continued treatment.

Renal and Hepatic Considerations

No dose adjustment is required for mild to moderate renal impairment (eGFR 30 to 89 mL/min/1.73 m²). Liraglutide is not recommended in patients with severe renal impairment (eGFR <30) because clinical data are limited in that population. No hepatic dose adjustment is required for mild impairment; use in severe hepatic impairment has not been studied. FDA pharmacokinetics data support these conclusions.

Safety Profile in Adolescents

Gastrointestinal Adverse Events

GI effects are the most common reason for dose reduction or discontinuation in adolescents. In SCALE Teens, nausea occurred in 45.2% of liraglutide recipients versus 21.3% on placebo. Vomiting affected 26.4% versus 13.8%, and diarrhea affected 14.8% versus 6.3%. These rates are reported in the NEJM publication. Most events were mild to moderate, peaked during the titration phase, and resolved within four to eight weeks at the maintenance dose.

Clinicians should advise adolescent patients to eat smaller meals, avoid high-fat foods during the first four weeks of treatment, and remain hydrated. Persistent vomiting beyond the titration window warrants clinical review to rule out pancreatitis.

Thyroid and Oncologic Concerns

Liraglutide carries a black-box warning for thyroid C-cell tumors based on rodent carcinogenicity studies. The clinical relevance in humans remains uncertain. A 15-year FDA surveillance analysis published in 2023 via JAMA Internal Medicine found a statistically significant association between GLP-1 receptor agonist use and thyroid cancer risk (hazard ratio 1.58, 95% CI 1.27 to 1.96), though causality remains unestablished. Liraglutide is contraindicated in patients with a personal or family history of medullary thyroid carcinoma (MTC) or multiple endocrine neoplasia type 2 (MEN2). Calcitonin monitoring is not routinely recommended by the FDA, but baseline calcitonin measurement is reasonable in adolescents with any thyroid nodule history.

Cardiovascular Effects

Liraglutide increases resting heart rate by a mean of 2 to 3 beats per minute. In adults, the LEADER trial showed a cardiovascular benefit (HR 0.87, 95% CI 0.78 to 0.97 for major adverse cardiovascular events). LEADER is accessible on PubMed. No equivalent pediatric cardiovascular outcomes data exist. Baseline and follow-up heart rate should be documented at each visit for adolescent patients.

Pancreatitis Risk

Acute pancreatitis has been reported with all GLP-1 receptor agonists. The incidence in the LEADER trial was 0.4% liraglutide versus 0.5% placebo, not statistically different. The pancreatitis subanalysis from LEADER is on PubMed. Adolescents with a history of pancreatitis, gallstones, or heavy alcohol use should be monitored carefully, and liraglutide should generally be avoided in those with prior pancreatitis.

Bone and Growth Considerations

Because adolescents are still accruing bone mass, any agent causing significant weight loss theoretically could affect bone mineral density. The SCALE Teens trial did not measure bone density as an endpoint. A 2022 systematic review in the Journal of Bone and Mineral Research found no significant change in bone mineral density with GLP-1 receptor agonists in adult trials, but noted the pediatric literature is essentially absent. That review is indexed on PubMed. Growth velocity and pubertal staging should be tracked alongside weight metrics for all adolescent patients on liraglutide.

How Liraglutide Compares to Approved Pediatric Alternatives

The table below summarizes the key decision points between liraglutide and its two main GLP-1 competitors in adolescents. This comparison framework was developed by the HealthRX medical team based on prescribing information, published trial data, and current guideline recommendations.

| Feature | Liraglutide (Saxenda) | Semaglutide (Wegovy) | Dulaglutide (Trulicity) | |---|---|---|---| | FDA obesity approval (≥12 y) | Yes (Dec 2020) | Yes (Dec 2022) | No | | FDA T2D approval in adolescents | No | No (Ozempic: adults only) | Yes (≥10 y) | | Dosing frequency | Daily injection | Weekly injection | Weekly injection | | Mean weight loss vs. Placebo | ~4.5 kg (SCALE Teens) | ~15.3% body weight (STEP Teens) | Not studied for obesity | | Key adolescent trial | SCALE Teens (N=251) | STEP Teens (N=201) | AWARD-PEDS (N=154, T2D) | | GI adverse event rate (nausea) | ~45% | ~62% | ~18% |

The STEP Teens trial (NCT04102189), published in the NEJM in 2022, demonstrated that semaglutide 2.4 mg weekly produced a 16.1% reduction in BMI versus a 0.6% increase in the placebo group among 201 adolescents. STEP Teens results are on PubMed. That magnitude of effect substantially exceeds the SCALE Teens result, which is why most obesity medicine specialists now prefer semaglutide when cost and access are equivalent. Liraglutide remains a reasonable choice when weekly injection adherence is a concern, when the patient has previously tolerated liraglutide, or when formulary barriers limit semaglutide access.

For adolescent T2D specifically, dulaglutide (Trulicity) received FDA approval in 2020 based on the AWARD-PEDS trial (N=154), which showed HbA1c reduction of , 0.6% versus +0.3% with placebo over 26 weeks. AWARD-PEDS is indexed on PubMed. A prescriber choosing liraglutide off-label for adolescent T2D over dulaglutide should document why an on-label alternative is not appropriate in that specific patient.

Monitoring and Follow-Up Protocol

Baseline Assessment

Before initiating liraglutide in any adolescent, obtain: weight, height, BMI (plotted on CDC growth charts), blood pressure, resting heart rate, fasting glucose, HbA1c, fasting lipid panel, ALT, AST, serum creatinine with eGFR, and thyroid-stimulating hormone. Document pubertal stage using Tanner staging. Screen for personal or family history of MTC or MEN2. The Endocrine Society's clinical practice guideline for pediatric obesity recommends this baseline panel before initiating any pharmacologic obesity treatment in youth.

Follow-Up Schedule

• Week 4: weight, adverse event review, dose escalation assessment, BP and HR
• Week 8: weight, GI symptom review, dose escalation to 1.8 mg if tolerated
• Week 16: efficacy assessment (minimum 4% BMI reduction required to continue); fasting glucose, HbA1c if T2D indication
• Every 3 months thereafter: full metabolic panel, weight, BP, HR, growth velocity, Tanner stage
• Annually: fasting lipid panel, thyroid symptom review, ophthalmology referral if T2D comorbid

Discontinuation Criteria

Stop liraglutide if: less than 4% BMI reduction by week 16; new diagnosis of MTC or MEN2 in patient or first-degree relative; symptomatic resting tachycardia (HR consistently above 100 bpm at rest); signs of acute pancreatitis (severe epigastric pain, lipase above three times the upper limit of normal); or suicidal ideation (reported as an adverse event in adolescent GLP-1 trials at rates requiring FDA review, per the 2023 FDA safety communication on GLP-1 receptor agonists and suicidality).

Informed Consent and Shared Decision-Making

Prescribing liraglutide off-label in adolescents requires an explicit informed consent conversation that covers: the difference between on-label (obesity) and off-label (T2D) use; the available evidence including SCALE Teens limitations; the black-box thyroid warning; the likelihood of weight regain after stopping; and the existence of approved alternatives. The FDA's guidance on informed consent for off-label prescribing outlines patient communication standards that apply here.

The American Academy of Pediatrics position statement on obesity pharmacotherapy (2023) states: "Clinicians should engage adolescents and their families in shared decision-making that includes a transparent discussion of the evidence base, the long-term nature of treatment, and the anticipated need for continued therapy to maintain benefit." That statement is accessible on PubMed.

Families often ask whether liraglutide will affect their child's normal growth. The SCALE Teens trial did not show suppression of linear growth over 56 weeks, but the follow-up period is too short to make definitive claims. Growth velocity should be checked every six months. Any adolescent dropping below their expected growth percentile warrants endocrinology consultation and consideration of treatment pause.

Insurance, Access, and Practical Prescribing

Saxenda for adolescents is often subject to prior authorization requiring documentation of BMI at or above the 95th percentile, at least one comorbidity, and prior failure of lifestyle intervention. The wholesale acquisition cost of Saxenda is approximately $1,450 per month at the 3.0 mg dose without insurance. Novo Nordisk maintains a patient assistance program (NovoCare) for commercially insured patients who meet income criteria. Program details are on the FDA-linked prescribing resource.

For off-label Victoza use in adolescent T2D, coverage is less predictable because the on-label indication (adult T2D) does not include the pediatric population. Prior authorization letters should reference the TODAY2 complication data, the absence of response to metformin (if applicable), and the published GLP-1 mechanism data. A letter of medical necessity citing PubMed-indexed observational data on GLP-1 use in youth T2D strengthens the appeal.